Acute promyelocytic leukemia: long-term outcomes from the HARMONY project
In this medfyle
The HARMONY project analyzed long-term outcomes of APL patients diagnosed between 1999 and 2022, comparing ATRA-ATO therapy with idarubicin-based chemotherapy (AIDA-like CHT) using data from international trials and European registries to evaluate treatment outcomes and identify prognostic factors. Findings revealed ATRA-ATO significantly improved 7-year overall survival (91% vs. 81%), event-free survival (89% vs. 71%), and reduced relapse rates (3% vs. 13%). Age and high Sanz risk scores were linked to increased early death risk. The study underscores ATRA-ATO’s superior efficacy regardless of patient age or risk score and highlights the need to address early death, especially in older and high-risk patients. These results redefine APL treatment and patient care strategies.
About this Medfyle
©2025 Medfyle. All rights reserved.
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in Blood, American Society of Hematology's official journal.
Original article: Voso MT, Guarnera L, Lehmann S, Döhner K, Döhner H, Platzbecker U, Russell N, Dillon R, Thomas I, Ossenkoppele G, Haferlach T, Vignetti M, La Sala E, Piciocchi A, Fazi P, Ramiro AV, Giménez LT, Gurnari C, Bullinger L, Hernández-Rivas JM. Acute promyelocytic leukemia: long-term outcomes from the HARMONY project. Blood. 2025 Jan 9;145(2):234-243.
